AM obtained most funding for the study and oversaw the study's conduct, developed the study protocols and provided guidance on study design and methods.
During the double-blind treatment period, patients and all personnel involved with the study's conduct or interpretation remained blinded to study drug codes.
Information's source of the study's conduct were collected: word-of-mouth, posters, Rouen University Hospital website, newspapers, radio, social networks, and others (several answers possible).
Personnel involved in plasma assays for evaluating population pharmacokinetics did not have access to the randomization schedule and were not otherwise involved in the study's conduct.
AHL obtained funding for the study, oversaw the study's conduct, developed and implemented the study protocols, oversaw research assistants, and wrote the initial and final drafts of the manuscript.
To determine the price per gram, the study's authors conducted surveys at the local level, adjusting their findings with statistics obtained from the 2017 World Drug Report by the UNODC.
LB planned the study's experiments, conducted the cell culture experiments, analyzed the signaling assays and prepared the manuscript.
OAF participated in the design of the study's methodology, conducted the analysis, interpretation of data and prepared the manuscript for final publication.
CE participated in the design of the study's methodology, conducted the analysis and interpretation of data and prepared the final manuscript for publication.
The Regional Committee for Medical and Health Research Ethics had no objections to the study's conduction, which was conducted according to the Declaration of Helsinki.
